RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > In Focus: Due Diligence

In Focus: Due Diligence

Posted 01 July 2009

This month we venture into the business side of regulatory with an issue concentrating on due diligence. Due diligence is usually thought of as an investigation of facts about a company or product by a concerned party, often a potential buyer. In the regulatory context, we would normally expect to see due diligence conducted as part of the acquisition of a company or product line. Particularly in the drug world, the regulatory status of products can be a deciding factor in a sale or merger. However, due diligence could also be internal: confirmation by management or others that certain regulatory steps have been taken, or that products are properly licensed and procedures correctly dealt with.


© 2022 Regulatory Affairs Professionals Society.